Onward Medical N.V. (ONWD) - Total Assets
Based on the latest financial reports, Onward Medical N.V. (ONWD) holds total assets worth €56.41 Million EUR (≈ $65.95 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Onward Medical N.V. net assets for net asset value and shareholders' equity analysis.
Onward Medical N.V. - Total Assets Trend (2017–2024)
This chart illustrates how Onward Medical N.V.'s total assets have evolved over time, based on quarterly financial data.
Onward Medical N.V. - Asset Composition Analysis
Current Asset Composition (December 2024)
Onward Medical N.V.'s total assets of €56.41 Million consist of 81.8% current assets and 18.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 77.2% |
| Accounts Receivable | €321.00K | 0.4% |
| Inventory | €102.00K | 0.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €8.46 Million | 10.9% |
| Goodwill | €1.96 Million | 2.5% |
Asset Composition Trend (2017–2024)
This chart illustrates how Onward Medical N.V.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ONWD stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Onward Medical N.V.'s current assets represent 81.8% of total assets in 2024, a decrease from 91.5% in 2017.
- Cash Position: Cash and equivalents constituted 77.2% of total assets in 2024, down from 88.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 10.9% of total assets.
Onward Medical N.V. Competitors by Total Assets
Key competitors of Onward Medical N.V. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Onward Medical N.V. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.34 | 3.65 | 5.19 |
| Quick Ratio | 4.30 | 3.65 | 5.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €34.93 Million | €25.24 Million | €9.89 Million |
Onward Medical N.V. - Advanced Valuation Insights
This section examines the relationship between Onward Medical N.V.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.36 |
| Latest Market Cap to Assets Ratio | 2.24 |
| Asset Growth Rate (YoY) | 78.2% |
| Total Assets | €77.77 Million |
| Market Capitalization | $174.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Onward Medical N.V.'s assets at a significant premium (2.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Onward Medical N.V.'s assets grew by 78.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Onward Medical N.V. (2017–2024)
The table below shows the annual total assets of Onward Medical N.V. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €77.77 Million ≈ $90.92 Million |
+78.25% |
| 2023-12-31 | €43.63 Million ≈ $51.01 Million |
-43.04% |
| 2022-12-31 | €76.59 Million ≈ $89.55 Million |
-26.91% |
| 2021-12-31 | €104.80 Million ≈ $122.52 Million |
+638.52% |
| 2020-12-31 | €14.19 Million ≈ $16.59 Million |
-39.22% |
| 2019-12-31 | €23.34 Million ≈ $27.29 Million |
+144.19% |
| 2018-12-31 | €9.56 Million ≈ $11.18 Million |
+16.83% |
| 2017-12-31 | €8.18 Million ≈ $9.57 Million |
-- |
About Onward Medical N.V.
Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company engages in developing ARCEX, a technology to enhance hand strength and sensation for individuals with SCI; ARCIM, a spinal cord stimulation system designed to address blood pressure instability and other symptoms in people wit… Read more